- Acts on
- Pituitary, to release growth hormone
- FDA-approved example
- Tesamorelin (HIV lipodystrophy)
- Sermorelin today
- Compounded only; not FDA-approved
- Monitoring
- IGF-1, blood sugar
How the growth hormone signal works
Your hypothalamus releases GHRH in pulses. The pituitary responds by releasing growth hormone (GH), which in turn prompts the liver to make IGF-1, the hormone behind many of GH's effects on muscle, bone and metabolism. GH and IGF-1 levels usually decrease with age.
A GHRH analog works upstream of GH. Rather than replacing growth hormone directly, it stimulates the pituitary to release its own, which means the body's normal feedback controls stay partly in place.
Examples and their FDA status
The best-known GHRH analogs differ a lot in their regulatory standing:
- Tesamorelin (Egrifta SV): FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for weight loss or anti-aging.
- Sermorelin: once FDA-approved as Geref for growth hormone deficiency in children and for testing pituitary function. The manufacturer discontinued it, and the FDA withdrew the approvals in 2009; in 2013 the FDA determined the withdrawal wasn't for safety or effectiveness reasons. No FDA-approved sermorelin is currently marketed. Sermorelin used today is compounded and not FDA-approved.
- CJC-1295: an investigational GHRH analog that is not FDA-approved. It was among the substances nominated for the FDA's compounding bulks list and later withdrawn from consideration.
What the evidence shows
Tesamorelin's approval rests on controlled trials in a specific population. For the uses GHRH analogs are often marketed for in wellness settings, such as anti-aging, body composition, sleep or recovery in healthy adults, high-quality human evidence is limited. Raising IGF-1 is a measurable lab effect, but that doesn't establish that a person will live longer or healthier.
Safety considerations
The tesamorelin label offers a useful guide to the risks of pushing up growth hormone, because it's the best-studied drug in the class:
- It shouldn't be used with active cancer, because GH and IGF-1 can promote cell growth.
- It's not for people with pituitary disease, pituitary surgery or head radiation, or during pregnancy.
- It can raise blood sugar and worsen glucose control.
- It can cause fluid retention, joint pain and carpal tunnel–type symptoms.
- IGF-1 levels should be monitored.
At HealifyMD
Sermorelin ODT is offered as a compounded, not FDA-approved, treatment after a clinician review. Your clinician sets any dosing and monitoring plan and will discuss the limited human evidence; IGF-1 testing may be part of that plan.
If you have a history of cancer, diabetes or a pituitary condition, make sure your clinician knows before any growth hormone–related treatment is considered.
GHRH analog: common questions
Is a GHRH analog the same as growth hormone?
No. A GHRH analog prompts your pituitary to release its own growth hormone, while growth hormone therapy replaces it directly.
Is sermorelin FDA-approved?
Not currently. Its earlier approval as Geref was withdrawn after the manufacturer stopped making it. Compounded sermorelin is not FDA-approved.
What is tesamorelin approved for?
Reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It isn't approved for weight loss.
Do GHRH analogs slow aging?
There's no solid human evidence that they slow aging or extend life. Most claims rely on lab markers such as IGF-1 or on small studies.
Who should avoid GHRH analogs?
People with active cancer, pituitary disorders or who are pregnant, and those with poorly controlled diabetes should generally avoid them.
Why is IGF-1 checked?
IGF-1 reflects growth hormone activity, so it helps show whether treatment is pushing levels too high.
Sources
We cite government agencies, professional societies and peer-reviewed research. See our editorial policy.
- EGRIFTA SV (tesamorelin) prescribing informationDailyMed (U.S. National Library of Medicine)
- Determination That GEREF (Sermorelin Acetate) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness (2013)Federal Register (U.S. Food and Drug Administration)
- Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety RisksU.S. Food and Drug Administration
- Aging changes in hormone productionMedlinePlus (U.S. National Library of Medicine)